Residual Effects of Low-Dose Sublingual Zolpidem on Highway Driving Performance the Morning after Middle-of-the-Night Use
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
STUDY OBJECTIVE: To evaluate next-morning driving performance after middle-of-the-night use of zolpidem 3.5 mg in a buffered sublingual formulation (ZST). DESIGN: Single-center, four-period, randomized, double-blind, placebo-controlled, crossover study. SETTING: Maastricht University, The Netherlands. PARTICIPANTS: Forty healthy volunteers (20 females). INTERVENTIONS: Single dose of ZST administered in the middle of the night at 3 and 4 h before driving, zopiclone 7.5 mg at bedtime 9 h before driving, and placebo. MEASUREMENTS: Performance in a 100-km standardized highway driving test in normal traffic measuring standard deviation of lateral position (SDLP) - an index of weaving. Drug-placebo changes in SDLP > 2.5 cm were considered to reflect clinically relevant driving impairment. RESULT: For ZST, Max McNemar symmetry analyses showed that the proportion of drivers classified as impaired was increased 3 h after dosing (P < 0.012), but not 4 h after dosing. Mean increases in SDLP from placebo, although statistically significant, were small (1.46 cm [P < 0.0001] at 3 h and 0.83 cm [P = 0.0174] at 4 h). The morning after zopiclone, 45% of the drivers were classified as impaired with a mean increase in SDLP of 2.46 cm (P < 0.0001). There were no significant sex differences in effects of ZST and zopiclone. CONCLUSION: Zolpidem 3.5 mg in a buffered sublingual formulation has a minimal risk of impairing driving performance in the morning ≥ 4 hours after middle-of-the night use. When taken 3 hours before driving, the drug may have impairing effects so caution should be exercised if medication is taken other than as indicated. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT01106859; Trial Name: Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet; http://clinicaltrials.gov/ct2/show/NCT01106859.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olubodun, J. O., Ochs, H. R., Von Moltke, L. L., Roubenoff, R., Hesse, L. M., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01852.x · Cited by 104
Cited by
Brandt, J., & Leong, C. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0207-7 · Cited by 356
Bos, F. M., Schoevers, R. A., & aan het Rot, M. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.008 · Cited by 81
Zhou, M., Tang, J., Li, S., Li, Y., & Zhao, M. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.1029554 · Cited by 24
“…2012, 2013, 2014, 2016, 2017, 2020; Hoever et al., 2012, 2013; Uchimura et al., 2012a,b; Sun et al., 2013; Leufkens et al., 2014; Tek et al., 2014; Vermeeren et al., 2014, 2016, 2019; Spierings et al., 2015; Connor et al., 2016; Dauvilliers et al., 2020; Dopheide, 2020; Karppa et al., 2020;…”
Metadata
- Authors
- Vermeeren, A., Vuurman, E. F. P. M., Leufkens, T. R. M., Van Leeuwen, C. J., Van Oers, A. C. M., Laska, E., Rico, S., Steinberg, F., & Roth, T.
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-01
- Volume
- 37
- Issue
- 3
- Pages
- 489-496
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W1972378992
- Cited by
- 45
- References
- 1
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Residual Effects of Low-Dose Sublingual Zolpidem on Highway Driving Performance the Morning after Middle-of-the-Night Use. https://app.cochat.ai/papers/10.5665/sleep.3482
- The paper
- Vermeeren, A., Vuurman, E. F. P. M., Leufkens, T. R. M., Van Leeuwen, C. J., Van Oers, A. C. M., Laska, E., Rico, S., Steinberg, F., & Roth, T. (2014). Residual Effects of Low-Dose Sublingual Zolpidem on Highway Driving Performance the Morning after Middle-of-the-Night Use. Sleep. https://doi.org/10.5665/sleep.3482
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.